iRhythm Technologies Inc
$ 121.46
-0.40%
23 Apr - close price
- Market Cap 4,006,518,000 USD
- Current Price $ 121.46
- High / Low $ 122.48 / 119.42
- Stock P/E N/A
- Book Value 4.73
- EPS -1.39
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.02 %
- ROE -0.37 %
- 52 Week High 212.00
- 52 Week Low 103.16
About
iRhythm Technologies, Inc., a digital healthcare company, offers ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company is headquartered in San Francisco, California.
Analyst Target Price
$195.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-10-30 | 2025-07-30 | 2025-04-30 | 2025-02-20 | 2024-10-30 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 0.17 | 0.06 | -0.32 | -0.95 | 0.01 | -1.26 | -0.61 | -1.23 | -1.26 | -0.89 | -0.61 | -1.1 |
| Estimated EPS | 0.01 | -0.32 | -0.5278 | -0.6886 | -0.28 | -0.57 | -0.89 | -0.96 | -0.6 | -0.66 | -0.78 | -0.9 |
| Surprise | 0.16 | 0.38 | 0.2078 | -0.2614 | 0.29 | -0.69 | 0.28 | -0.27 | -0.66 | -0.23 | 0.17 | -0.2 |
| Surprise Percentage | 1600% | 118.75% | 39.371% | -37.9611% | 103.5714% | -121.0526% | 31.4607% | -28.125% | -110% | -34.8485% | 21.7949% | -22.2222% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.56 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IRTC
2026-04-23 09:09:33
iRhythm Technologies reported strong Q2 2024 results with revenue up 19.3% year-over-year to $148.0 million, driven by demand for its Zio product and expansion into new markets. The company raised its full-year 2024 revenue guidance to $580-$590 million and improved its outlook for gross margin and adjusted EBITDA margin. IRTC also addressed an FDA warning letter and announced a CFO transition.
2026-04-22 09:09:33
iRhythm Holdings reported positive clinical data for its Zio cardiac monitoring device and launched iRhythm Academy, an educational platform for healthcare professionals. These developments are expected to strengthen Zio's market position, particularly in high-risk patient populations, and improve clinician engagement. While these strides bolster iRhythm's investment narrative, competitive pressures, reimbursement uncertainties, and the need for sustained GAAP profitability remain key concerns for investors.
2026-04-22 01:09:34
iRhythm Technologies reported favorable analysis results for its Zio cardiac monitoring device and launched iRhythm Academy, an education platform for healthcare professionals, at the American College of Cardiology 2026 Annual Scientific Sessions. These developments could strengthen Zio's position in managing high-risk patient populations and deepen clinician engagement. However, investors are advised to also consider competitive pressures, reimbursement uncertainties, and the need for durable GAAP profitability.
2026-04-21 22:24:00
This article from Stock Traders Daily analyzes Irhythm Technologies Inc. (NASDAQ: IRTC) using AI-generated quant signals. It provides key findings indicating neutral near-term readings, a stalling strong mid-term sentiment, and an ongoing breakdown with elevated downside risk. The analysis includes institutional trading strategies for different risk profiles, multi-timeframe signal analysis, and real-time signals for entry and exit points.
2026-04-20 20:08:47
iRhythm Technologies (IRTC) has seen its stock price drop by 31.2% in the last six months, prompting investors to re-evaluate the company. Despite positive aspects like strong revenue growth (23% CAGR over five years) and an expanding free cash flow margin (4.6% TTM), its relatively small scale ($747.1 million revenue) presents challenges in a highly regulated healthcare industry. The article concludes that IRTC's positive characteristics outweigh the negatives, and the stock trades at 40.7x forward EV-to-EBITDA.
2026-04-19 07:39:54
InvestingPro's Fair Value analysis accurately predicted a significant decline in iRhythm Technologies (IRTC) stock. The company was flagged as overvalued in November 2025 at $187.30, and subsequently plummeted nearly 40% to $112.97 by March 2026, validating the tool's ability to identify mispriced securities. This case highlights how data-driven methodologies can help investors make informed decisions and avoid costly investment errors.
